Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 45(3); 2021 > Article
Response
Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015) (Diabetes Metab J 2021;45:115-9)
Seong-Su Moon1, Chong Hwa Kim2, Seon Mee Kang3, Eun Sook Kim4, Tae Jung Oh5, Jae-Seung Yun6, Ho Chan Cho7, Dae Jung Kim8, Tae Sun Park9orcid
Diabetes & Metabolism Journal 2021;45(3):459-460.
DOI: https://doi.org/10.4093/dmj.2021.0084
Published online: May 25, 2021
  • 3,646 Views
  • 74 Download
  • 1 Web of Science
  • 1 Crossref
  • 1 Scopus

1Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, Korea

2Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea

3Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

4Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

5Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

6Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea

7Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea

8Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea

9Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea

Corresponding author: Tae Sun Park orcid Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, 20 Geonji-ro, Deokjin-gu, Jeonju 54907, Korea E-mail: pts@jbnu.ac.kr

Copyright © 2021 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

We appreciate the interest and comments of Professor Tímea Csákvári and Imre Boncz et al. on our study, “Status of diabetic neuropathy in Korea: a National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015),” which was published in Diabetes and Metabolism Journal [1].
In our study, we investigated prevalence of diabetic neuropathy (DN), patient characteris-tics, and pharmacological treatments using a National Health Insurance Service-National Sample Cohort (NHIS-NSC). DN was defined using diagnostic codes or medications prescribed by clinicians rather than clinical diagnostic criteria and neurologic examinations. In your studies, data were derived from the database of the National Health Insurance Fund Administration (NHIFA) 2018, the sole health insurance provider of Hungary [2,3]. This database is different from ours.
In your comments, International Classification of Diseases (ICD) codes of DN can be used for neurological complications (e.g., G73.0 or E10.7–E14.7, E10.8–E14.8). However, in our cohort, DN patients were included based on ICD-10 codes (E10.4–E14.4, G59.0, G63.2, G99.0) or history of DN management drug plus glucose lowering agent to exclude duplication. Therefore, our study population covered almost all DN complications patients, unlike your study population, which included only G63.20 and E11.4 ICD-10 codes. This suggests quite different study populations [2,3].
First, DN prevalence rate was different between our study and yours. Previously, we had reported a 33.5% prevalence rate of diabetic peripheral neuropathy in the Korean population in a nationwide hospital-based multicenter study conducted by the Diabetic Neuropathy Study Group of the Korean Diabetes Association [4]. Discrepancy from your prevalence rate probably is due to difference of study populations, lack of standard diagnostic criteria, and use of different diagnostic codes. Therefore, our current study prevalence rate of DN might had been underestimated compared to previous studies. However, our current prevalence rate was based on real-world data.
The second difference between studies was prescription rate of management drugs for DN patients. We defined the prescription rate for DN based on a routine clinical care setting using our insurance coverage, which limited us from directly comparing the prescription rates between two countries. Therefore, we recommend that you analyze your exact DN management drug prescription rate and compare to our data.
The third difference is that in prevalence rates for diabetic microvascular complication.
Diabetes fact sheet in Korea [5] showed higher prevalence rates for diabetic microvascular diseases such as DN, diabetic retinopathy, and diabetic nephropathy compared to your nationwide data. We do not know the exact causes of this difference between Korea and Hungry. If we have a chance to analyze the two nations’ medical insurance system including coding and claiming, we can find the difference factor.
We would like to thank Professor Tímea Csákvári again for your comprehensive review and comments on our study. We fully agreed that prevention of DN, adequate management, and real-world health insurance claims data can contribute significantly to efforts aimed at lowering the economic and societal burden of DN.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

  • 1. Moon SS, Kim CH, Kang SM, Kim ES, Oh TJ, Yun JS, et al. Status of diabetic neuropathy in Korea: a National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015). Diabetes Metab J 2021;45:115-9.ArticlePubMedPDF
  • 2. Boncz I, Ponusz R, Elmer D, Nemeth N, Horvath L, Sebestyen A, et al. Epidemiological disease burden of diabetic polyneuropathy based on routinely collected health insurance claims data. Value Health 2020;23(Suppl 1):S121-2.
  • 3. Boncz I, Ponusz R, Elmer D, Nemeth N, Horvath L, Sebestyen A, et al. Annual health insurance treatment cost of diabetic polyneuropathy based on routinely collected financing data. Value Health 2020;23(Suppl 1):S117.
  • 4. Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, et al. Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with type 2 diabetes in Korea. Diabet Med 2012;29:e290-6.ArticlePubMed
  • 5. Korean Diabetes Association: Diabetes fact sheet in Korea Available from: https://www.diabetes.or.kr/pro/news/admin.php?mode=list&category=B (cited 2021 May 13).

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Comorbidity Patterns and Management in Inpatients with Endocrine Diseases by Age Groups in South Korea: Nationwide Data
      Sung-Soo Kim, Hun-Sung Kim
      Journal of Personalized Medicine.2023; 14(1): 42.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015) (Diabetes Metab J 2021;45:115-9)
      Diabetes Metab J. 2021;45(3):459-460.   Published online May 25, 2021
      Close
    • XML DownloadXML Download
    Related articles

    Diabetes Metab J : Diabetes & Metabolism Journal